Edition:
United States

Xencor Inc (XNCR.OQ)

XNCR.OQ on NASDAQ Stock Exchange Global Market

42.33USD
20 Jul 2018
Change (% chg)

$0.02 (+0.05%)
Prev Close
$42.31
Open
$42.24
Day's High
$43.40
Day's Low
$42.24
Volume
63,235
Avg. Vol
143,915
52-wk High
$43.40
52-wk Low
$19.00

Chart for

About

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials... (more)

Overall

Beta: 1.64
Market Cap(Mil.): $2,353.50
Shares Outstanding(Mil.): 55.63
Dividend: --
Yield (%): --

Financials

  XNCR.OQ Industry Sector
P/E (TTM): -- 217.69 33.34
EPS (TTM): -0.84 -- --
ROI: -9.39 -3.65 13.18
ROE: -9.49 -5.62 15.09

BRIEF-Xencor Reports Q1 Loss Per Share $0.62

* Q1 EARNINGS PER SHARE VIEW $-0.46 -- THOMSON REUTERS I/B/E/S

May 07 2018

BRIEF-Xencor Says Public Offering Of 7.30 Mln Common Shares Priced At $31 Per Share

* XENCOR ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Mar 20 2018

BRIEF-Xencor Files For Potential Mixed Shelf Offering

* XENCOR INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING ‍​ Source text: (http://bit.ly/2G8MdV1) Further company coverage:

Mar 19 2018

BRIEF-Xencor Announces Proposed Public Offering Of Common Stock

* XENCOR, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Mar 19 2018

BRIEF-Xencor Reports Q4 Loss Per Share $0.25

* XENCOR REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 27 2018

BRIEF-Xencor Doses First Patient In Phase 1 Study Of Xmab®18087,An Antibody For Treatment Of Neuroendocrine Tumors And Gastrointestinal Stromal Tumors

* XENCOR DOSES FIRST PATIENT IN PHASE 1 STUDY OF XMAB®18087 BISPECIFIC TUMOR TARGETING ANTIBODY FOR THE TREATMENT OF NEUROENDOCRINE TUMORS AND GASTROINTESTINAL STROMAL TUMORS

Feb 22 2018

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $37.33 -0.03
Novartis AG (NOVN.S) CHF82.20 +1.24
Roche Holding Ltd. (ROG.S) CHF234.00 +2.05
Roche Holding Ltd. (RO.S) CHF238.60 +2.80
AstraZeneca plc (AZN.L) 5,589.00 -20.00
GlaxoSmithKline plc (GSK.L) 1,549.80 -8.20
AbbVie Inc (ABBV.N) $88.91 -1.04
Bristol-Myers Squibb Co (BMY.N) $56.71 +0.17
Bristol-Myers Squibb Co (BMYMP.PK) $950.15 --
Amgen, Inc. (AMGN.OQ) $190.49 -1.27

Earnings vs. Estimates